Literature DB >> 33128203

Body size and weight change over adulthood and risk of breast cancer by menopausal and hormone receptor status: a pooled analysis of 20 prospective cohort studies.

Piet A van den Brandt1,2, Regina G Ziegler3, Molin Wang4,5,6, Tao Hou7, Ruifeng Li7, Hans-Olov Adami8,9, Claudia Agnoli10, Leslie Bernstein11, Julie E Buring4,12, Yu Chen13, Avonne E Connor14, A Heather Eliassen4,6, Jeanine M Genkinger15,16, Gretchen Gierach3, Graham G Giles17,18,19, Gary G Goodman20, Niclas Håkansson21, Vittorio Krogh10, Loic Le Marchand22, I-Min Lee4,12, Linda M Liao3, M Elena Martinez23,24, Anthony B Miller25, Roger L Milne17,18,19, Marian L Neuhouser20, Alpa V Patel26, Anna Prizment27,28, Kim Robien29, Thomas E Rohan30, Norie Sawada31, Leo J Schouten32, Rashmi Sinha3, Rachael Z Stolzenberg-Solomon3, Lauren R Teras26, Shoichiro Tsugane31, Kala Visvanathan14, Elisabete Weiderpass33, Kami K White22, Walter C Willett4,6,7, Alicja Wolk21,34, Anne Zeleniuch-Jacquotte13, Stephanie A Smith-Warner4,7.   

Abstract

Associations between anthropometric factors and breast cancer (BC) risk have varied inconsistently by estrogen and/or progesterone receptor (ER/PR) status. Associations between prediagnostic anthropometric factors and risk of premenopausal and postmenopausal BC overall and ER/PR status subtypes were investigated in a pooled analysis of 20 prospective cohorts, including 36,297 BC cases among 1,061,915 women, using multivariable Cox regression analyses, controlling for reproductive factors, diet and other risk factors. We estimated dose-response relationships and tested for nonlinear associations using restricted cubic splines. Height showed positive, linear associations for premenopausal and postmenopausal BC risk (6-7% RR increase per 5 cm increment), with stronger associations for receptor-positive subtypes. Body mass index (BMI) at cohort baseline was strongly inversely associated with premenopausal BC risk, and strongly positively-and nonlinearly-associated with postmenopausal BC (especially among women who never used hormone replacement therapy). This was primarily observed for receptor-positive subtypes. Early adult BMI (at 18-20 years) showed inverse, linear associations for premenopausal and postmenopausal BC risk (21% and 11% RR decrease per 5 kg/m2, respectively) with stronger associations for receptor-negative subtypes. Adult weight gain since 18-20 years was positively associated with postmenopausal BC risk, stronger for receptor-positive subtypes, and among women who were leaner in early adulthood. Women heavier in early adulthood generally had reduced premenopausal BC risk, independent of later weight gain. Positive associations between height, baseline (adult) BMI, adult weight gain and postmenopausal BC risk were substantially stronger for hormone receptor-positive versus negative subtypes. Premenopausal BC risk was positively associated with height, but inversely with baseline BMI and weight gain (mostly in receptor-positive subtypes). Inverse associations with early adult BMI seemed stronger in receptor-negative subtypes of premenopausal and postmenopausal BC.

Entities:  

Keywords:  Body height; Body weight; Breast neoplasms; Cohort studies; Estrogen receptor; Weight change

Mesh:

Substances:

Year:  2020        PMID: 33128203      PMCID: PMC7847460          DOI: 10.1007/s10654-020-00688-3

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   12.434


  80 in total

1.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 2.  Adipose tissue as a source of hormones.

Authors:  P K Siiteri
Journal:  Am J Clin Nutr       Date:  1987-01       Impact factor: 7.045

3.  Adult weight change and risk of postmenopausal breast cancer.

Authors:  A Heather Eliassen; Graham A Colditz; Bernard Rosner; Walter C Willett; Susan E Hankinson
Journal:  JAMA       Date:  2006-07-12       Impact factor: 56.272

4.  The interaction between early-life body size and physical activity on risk of breast cancer.

Authors:  Hannah Oh; Caroline E Boeke; Rulla M Tamimi; Stephanie A Smith-Warner; Molin Wang; Walter C Willett; A Heather Eliassen
Journal:  Int J Cancer       Date:  2014-11-10       Impact factor: 7.396

5.  Baseline characteristics of participants in the Women's Health Study.

Authors:  K M Rexrode; I M Lee; N R Cook; C H Hennekens; J E Buring
Journal:  J Womens Health Gend Based Med       Date:  2000 Jan-Feb

6.  Adiposity Results in Metabolic and Inflammation Differences in Premenopausal and Postmenopausal Women Consistent with the Difference in Breast Cancer Risk.

Authors:  H Zhao; J Wang; D Fang; O Lee; R T Chatterton; V Stearns; S A Khan; S E Bulun
Journal:  Horm Cancer       Date:  2018-03-15       Impact factor: 3.869

Review 7.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies.

Authors:  Andrew G Renehan; Margaret Tyson; Matthias Egger; Richard F Heller; Marcel Zwahlen
Journal:  Lancet       Date:  2008-02-16       Impact factor: 79.321

8.  Quantitative association between body mass index and the risk of cancer: A global Meta-analysis of prospective cohort studies.

Authors:  Xuexian Fang; Jiayu Wei; Xuyan He; Jia Lian; Dan Han; Peng An; Tianhua Zhou; Simin Liu; Fudi Wang; Junxia Min
Journal:  Int J Cancer       Date:  2018-05-13       Impact factor: 7.396

9.  Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk.

Authors:  Jane Green; Benjamin J Cairns; Delphine Casabonne; F Lucy Wright; Gillian Reeves; Valerie Beral
Journal:  Lancet Oncol       Date:  2011-07-22       Impact factor: 41.316

10.  Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.

Authors: 
Journal:  Lancet       Date:  2019-08-29       Impact factor: 79.321

View more
  7 in total

1.  Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors.

Authors:  Annie Tang; Caitlin M Cohan; Keith S Hansen; Genna Beattie; Heather I Greenwood; Rita A Mukhtar
Journal:  Breast Cancer Res Treat       Date:  2021-03-27       Impact factor: 4.872

Review 2.  The timing of adiposity and changes in the life course on the risk of cancer.

Authors:  Zhe Fang; Edward L Giovannucci
Journal:  Cancer Metastasis Rev       Date:  2022-07-30       Impact factor: 9.237

Review 3.  Is early-onset cancer an emerging global epidemic? Current evidence and future implications.

Authors:  Tomotaka Ugai; Naoko Sasamoto; Hwa-Young Lee; Mariko Ando; Mingyang Song; Rulla M Tamimi; Ichiro Kawachi; Peter T Campbell; Edward L Giovannucci; Elisabete Weiderpass; Timothy R Rebbeck; Shuji Ogino
Journal:  Nat Rev Clin Oncol       Date:  2022-09-06       Impact factor: 65.011

4.  Prevalence of Known Risk Factors in Uruguayan Women Treated for Breast Cancer at a University Hospital.

Authors:  Cecilia Castillo; Natalia Camejo; Ana Laura Hernandez; Nora Artagaveytia; Rafael Alonso; Lucia Delgado
Journal:  Breast Cancer (Auckl)       Date:  2021-04-12

5.  Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer.

Authors:  Elizabeth A Wellberg; Karen A Corleto; L Allyson Checkley; Sonali Jindal; Ginger Johnson; Janine A Higgins; Sarina Obeid; Steven M Anderson; Ann D Thor; Pepper J Schedin; Paul S MacLean; Erin D Giles
Journal:  Breast Cancer Res       Date:  2022-06-20       Impact factor: 8.408

6.  Postmenopausal overweight and breast cancer risk; results from the KARMA cohort.

Authors:  Marie Klintman; Ann H Rosendahl; Benjamin Randeris; Mikael Eriksson; Kamila Czene; Per Hall; Signe Borgquist
Journal:  Breast Cancer Res Treat       Date:  2022-08-30       Impact factor: 4.624

7.  Ethnicity and the tumour characteristics of invasive breast cancer in over 116,500 women in England.

Authors:  Toral Gathani; Gillian Reeves; John Broggio; Isobel Barnes
Journal:  Br J Cancer       Date:  2021-05-26       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.